TLR4/NF-κB-IN-1 (Compound 7x) is an orally available inhibitor that specifically targets the TLR4/NF-κB signaling pathway, offering anti-inflammatory effects and the ability to cross the blood-brain barrier. TLR4/NF-κB-IN-1 can reduce acute neuroinflammation in mice caused by LPS and downregulate the expression of TLR4, P-NF-κB and P-IκB-α proteins [1].
References:
[1]. Liang Xiong, et al. Design and synthesis of novel derivatives of bisepoxylignans as potent anti-inflammatory agents involves the modulation of the M1/M2 microglia phenotype via TLR4/NF-κB signaling pathway. Eur J Med Chem. 2025 Jan 15:282:117092.
References:
[1]. Liang Xiong, et al. Design and synthesis of novel derivatives of bisepoxylignans as potent anti-inflammatory agents involves the modulation of the M1/M2 microglia phenotype via TLR4/NF-κB signaling pathway. Eur J Med Chem. 2025 Jan 15:282:117092.